Abstract Details

Title Clinical outcome and prognostication of patients with inflammatory and immune myopathies with and without chemotherapy in the United States.

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P8 - Poster Session 8 (5:30 PM-6:30 PM)

Poster/Presentation
Number 11-011

Background Inflammatory and immune myopathy (IIM) is an umbrella term that comprises various types of myopathies based on the result of autoantibodies and clinical presentation. Very limited data is available on patients who were diagnosed with IIM and required chemotherapy for underlying malignancies.

Objective

To compare the clinical outcome and in-hospital complication risk with chemotherapy and without chemotherapy in patients with inflammatory and immune myopathies.

Design/Methods

We obtained data for IIM patients admitted to hospitals in the United States from 2017 to 2019 with a primary diagnosis of IIM using a large national database. We determined the rate and pattern of utilization of associated in-hospital outcomes of chemotherapy in this patient population.

Results

A total of 1072 patients had IIM out of which 63 (5.8%) received chemotherapy for the underlying malignancies. No racial differences were observed in both groups, however mean age for the patients who required chemotherapy was more than the non-chemotherapy group (72.7±11 vs 67.5±15, p <0.01). Patients who received chemotherapy had more in-hospital complications including, sepsis (25.1% vs. 11.6%, p<0.01), and acute kidney injury (23.8%% vs. 13.2%, p < 0.01). No significant difference was noticed in the length of stay during hospitalization in both groups. The number of deaths were higher in the chemotherapy group. In a further study of patients who died in the chemotherapy group, the risk of myocardial infarction (MI) was 16 times higher in comparison to the alive patients (p<0.01)

Conclusions In hospitalization complications such as sepsis and acute kidney injury were higher in the patients who received chemotherapy in IIM patients and patients who died had 16 times more risk of having MI. This study highlights the need of strict sepsis prevention protocols in this patient population. Further research is required to study the cardiac cause of death in these patients.

Authors/Disclosures
Baljinder Singh, MD PRESENTER	Dr. Singh has nothing to disclose.
Yixin Chen	No disclosure on file
Xueying Liu	No disclosure on file
Harmandeep Singh Brar	No disclosure on file
Rajeev Motiwala, MD, FAAN (NYU Langone School of Medicine)	Dr. Motiwala has nothing to disclose.
Simrandeep Brar (Texas Tech University)	No disclosure on file
Jacqueline Kraus, MD, PhD	Dr. Kraus has a non-compensated relationship as a Member with AAN that is relevant to AAN interests or activities.
Elina Zakin, MD (NYU Grossman School of Medicine)	The institution of Dr. Zakin has received research support from American Board of Psychiatry and Neurology.